Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSAAV gene therapy usually gets one shot before neutralizing antibodies lock the door. A Tianjin-Harbin team used protein language models to design peptides that mimic the viral shell, drawing antibodies off the real vector. In mice it worked only with an antibody-cleaving enzyme doing the heavy lifting.
A Lund University team infused a GIP-receptor or a GLP-1-receptor agonist into mice for a month. The two arms of the incretin drugs remodeled the heart in different directions, and the pattern split by sex.
A short peptide, braced with a hydrocarbon staple, bound CREB at low-nanomolar strength and choked lung cancer cells that had lost the LKB1 tumor suppressor, while mostly sparing cells that kept it. All in a dish. No animal has seen it yet.
In a matched US health-records study of obese asthma patients, GLP-1 users had about 56 percent fewer flares and fewer severe respiratory events over a year. Every outcome leaned the same way, which is also the signature of who gets the drug.
A Pediatrics study found GLP-1 prescriptions in American grade-schoolers with obesity jumped from 0.03 percent to 9.3 percent between 2019 and 2026. The prescriptions concentrated in the sickest children, but ran ahead of the long-term evidence.
A Nature Health analysis of 67,008 Reddit users on semaglutide and tirzepatide surfaced menstrual and body-temperature complaints that clinical trials never catalogued. It is a lead worth chasing, not proof of cause.
A single-center review of adolescents on liraglutide or semaglutide found no rise in suicidality and a drop in depression scores. The finding rests on fifteen paired depression screens.
A meta-analysis of twelve studies found depression and anxiety scores fell on CGRP-blocking migraine drugs. Almost none of that came from placebo-controlled trials, and the single controlled comparison came up empty.
Researchers fused a small-molecule FAP inhibitor onto a cyclic peptide so the radioligand grips its target twice. The heterobivalent design held in tumors longer and, carrying lutetium-177, slowed tumor growth more than the clinical benchmark FAP-2286 in mice.
A Mendelian randomization study found that genetically higher GLP-1 receptor activity tracked lower heart-failure risk, with about a quarter of the effect running through less of the inflammation enzyme MMP-1. The heart-failure estimate barely cleared significance, and no drug was given.
A Journal of Physiology study found that the calming peptide oxytocin quiets an inhibitory brake on the stomach's vagal circuit at baseline in female rats, whereas males need stress first. The stress switch is already thrown in females, a concrete mechanism for why gut-brain disorders hit women harder.
BDNF makes a terrible drug. A screening system built a rigid macrocyclic peptide that grips TrkB, then two copies were fused so the molecule clamps a pair of receptors and switches them on. It fired TrkB, lit ERK and AKT, and elongated axons in cultured neurons. No animal, no dosing, no disease model yet.
Eighteen reviews say GLP-1 drugs help in type 1 diabetes. A new overlap-informed umbrella review shows they re-pool the same few trials. Weight fell about 3.9 kg and insulin dropped, but time in range did not move, and the most certain findings were nausea, vomiting, and dropouts.
Peptide-4 binds Ndc80, half of the clamp that dividing cells use to grab spindle fibers, at 0.45 nanomolar and blocks its partnership with Nuf2. In liver-cancer cells it forced mitotic arrest and death, and it slowed tumors in mice. The target is a flat protein interface small molecules cannot hold, and the whole story is still preclinical.
In the first pediatric-specific study of its kind, 80 percent of adolescents on GLP-1 drugs still had solids on gastric ultrasound before surgery despite fasting more than twice the required time, against 5 percent of healthy controls. The standard preoperative fast did not empty their stomachs.